Table 2.
Characteristics of Studies Included in the Meta-Analysis With Respect to HCV-RNA Detection.
| Year | Author | HCV-GT | HIV | Country | Age (years) | Males (%) | Assay in DBS samples | Gold standard | Sample (n) | HCV-infected (n) | Se (%) | Sp (%) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2012 | Bennett et al.46 | 1a, 2b, 3a, 4a, 5, 6a | No | United Kingdom | — | — | TaqMan real-time PCR (In-house 2-step RT and PCR) | Real-time RT-PCR: m2000 rt (Abbott Molecular) | 80 | 57 | 100 | 95.8 |
| 2010 | De Crignis et al.47 | 1a, 1b, 2a, 3a | Yes | Italy | — | — | SYBR Green real-time RT-PCR for HCV and HIV detection | Real-time RT-PCR: VERSANT HCV RNA 3.0 b-DNA Assay (Siemens) | 25 | 16 | 93.8 | 100 |
| 2014 | Dokubo et al.27 | — | No | USA | < 30 | — | dHCV TMA (Novartis Vaccines and Diagnostics) | TMA: Procleix Ultrio Assay (Novartis Vaccines and Diagnostics) s | 132 | 48 | 89.6 | 100 |
| 2016 | Mössner et al.38 | — | Yes | Denmark | — | — | TMA: Procleix Ultrio Elite assay (Novartis Vaccines and Diagnostics) | TMA: Procleix Ultrio Elite Assay (Novartis Vaccines and Diagnostics) | 107 | 85 | 95.3 | 95.5 |
| 2013 | Ross et al.39 | — | No | Germany | — | — | TMA: VERSANT HCV RNA Qualitative Assay (Siemens) | TMA: VERSANT HCV RNA Qualitative Assay (Siemens) | 150 | 100 | 100 | 100 |
| 2018 | Saludes et al.45 | 1, 2, 3, 4 | No | Spain | — | — | QuantiFast Pathogen RT-PCR + IC Kit (QIAGEN) | Abbott RealTime HCV (Abbott Molecular) | 82 | 38 | 100 | 100 |
| 2012 | Santos et al.44 | No | Brazil | — | — | In-house qPCR | In-house qPCR | 168 | 101 | 98 | 94.3 | |
| 2002 | Solmone et al.48 | 1b, 2a, 2c, 3a, 4c, 4d | No | Italy | — | — | In-house 2-step RT and PCR | Amplicor HCV Monitor (Roche Molecular) TMA: VERSANT HCV RNA Qualitative Assay (Siemens) | 55 | 34 | 100 | 100 |
| 2002 | Solmone et al.48 | 1b, 2a, 2c, 3a, 4c, 4d | No | Italy | — | — | TMA Unspedified. | Amplicor HCV Monitor (Roche Molecular) TMA: VERSANT HCV RNA Qualitative Assay (Siemens) | 55 | 34 | 100 | 100 |
| 2016 | Soulier et al.9 | 1, 2, 3, 4, 5a, 6 | No | France | 54 | 55,2 | Real-time RT-PCR: Cobas Ampliprep/Cobas TaqMan HCV version 2 (Roche Molecular) | Real-time RT-PCR: Cobas Ampliprep/Cobas TaqMan HCV version 2 (Roche Molecular) | 511 | 315 | 97.1 | 100 |
| 2016 | Soulier et al.9 | 1, 2, 3, 4, 5a, 6 | No | France | 54 | 55,2 | Real-time RT-PCR: m2000rt (Abbott Molecular) | Real-time RT-PCR: m2000rt (Abbott Molecular) | 511 | 314 | 98.1 | 100 |
| 2018 | Vázquez-Morón et al.24 | 1a, 1b, 2, 3, 4, 5 | Yes | Spain | 44.3 | 66.9 | Quantitec SYBR Green RT-PCR One Step kit (Qiagen) | VERSANT HCV RNA 1.0 Assay | 139 | 108 | 99.1 | 100 |
Abbreviations: dHCV TMA, discriminatory HCV transcription-mediated amplification assay; GT, genotype; HCV, hepatitis C virus; HIV, human immunodeficiency virus; PCR, polymerase chain reaction; RT, reverse transcription; Se, sensitivity; Sp, specificity; TMA, transcription-mediated amplification.